Search Results
Your search for ,aDd matches 943 pages
Showing 501 - 550Resilience While Caring for Seriously Ill Patients: Skills and Strategies to Prevent Burnout
A career in oncology can be extremely rewarding. Fast-paced advances in research and treatment, exciting changes in the practice environment, and the opportunity to build strong relationships with and provide critical support to patients can be incredibly professionally satisfying—but they can...
Prostate Cancer Therapy in Evolution: Time to Rethink and Redirect?
The ASCO updated guidelines on the treatment of metastatic non-castrate prostate cancer penned by Morris and his colleagues1 provide valuable information annotated to the strengths of evidence in recently reported prostate cancer studies. CHAARTED, GETUG-AFU 15, LATITUDE, and STAMPEDE have...
Expert Point of View: Kenneth C. Anderson, MD, FASCO, Adam D. Cohen, MD, Craig Hofmeister, MD, MPH, and Bruce Cheson, MD
Kenneth C. Anderson, MD, FASCO, of Dana-Farber Cancer Institute, Boston, noted that the iNNOVATE trial is the first randomized comparison of ibrutinib (Imbruvica) plus rituximab (Rituxan) vs “a very active control—rituximab—to which 50% of patients responded.” The study showed that “the...
EHA 2018: Obinutuzumab or Rituximab Plus Chlorambucil in CLL
Data from the final analysis of the CLL11 study evaluating obinutuzumab (Gazyva)-based treatment in previously untreated chronic lymphocytic leukemia (CLL) was presented by Goede et al during the Presidential Symposium at the 23rd Annual Congress of the European Hematology Association (EHA)...
ASCO Clinical Practice Guideline Focused Update: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
As reported by Neelima Denduluri, MD, of US Oncology Network, Virginia Cancer Specialists, and colleagues in the Journal of Clinical Oncology, ASCO has issued a focused update on the clinical practice guideline on optimal chemotherapy and targeted therapy in early breast cancer. To develop the...
‘Pearls of Wisdom’ for Leadership and Success in Academic Medicine Gathered Over a 35-Year Career
Dr. Hayes, ASCO President 2016–2017, is Professor of Internal Medicine; Stuart B. Padnos Professor in Breast Cancer; and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor. AS I COMPLETE my 3-year term as ASCO President, I am...
2018 ASCO: Hyperthermic Intraperitoneal Chemotherapy Does Not Add Benefit in Patients With Advanced Colorectal Cancer
A randomized phase III clinical trial showed that people with advanced colorectal cancer may not need a frequently considered component of treatment—heated chemotherapy delivered to the abdomen during surgery. There was no difference in survival between patients with metastases in the abdomen ...
NCCN Names Wui-Jin Koh, MD, New Chief Medical Officer
The National Comprehensive Cancer Network® (NCCN®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer, a newly created position. Dr. Koh will add additional physician representation at NCCN headquarters, which includes Chief Executive Officer Robert W. Carlson, MD. Dr. Koh...
Expert Point of View: Howard Weinstein, MD
“These are excellent results, both overall and for patients randomly assigned to nelarabine with either high-dose methotrexate or escalated-dose methotrexate,” said Howard Weinstein, MD, Chief of Pediatric Hematology/Oncology at Massachusetts General Hospital, Boston, who was not involved in this...
National Comprehensive Cancer Network Announces New Chief Medical Officer
The National Comprehensive Cancer Network® (NCCN®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer, a newly created position for the nonprofit alliance of top U.S. cancer centers. Dr. Koh will add additional physician representation at NCCN headquarters, which...
ASBrS 2018: Regular Mammograms May Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment
Women with breast cancer who underwent regular mammographic screening were diagnosed with earlier-stage disease and treated with significantly less aggressive therapies than those who delayed or never underwent screening, according to new research presented at the American Society of Breast...
HPV-Related Cancers Like Mine Are Avoidable, So Why Aren’t More Kids Being Vaccinated?
The latest news from the Centers for Disease Control and Prevention about vaccination rates in the United States for human papillomavirus (HPV) is disappointing. It shows that in 2016, just 43.4% of adolescents (49.5% of females and 37.5% of males) were up-to-date with the recommended 3-dose HPV...
Using Video Decision-Support Tools to Facilitate End-of-Life Discussions With Patients
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. Research shows that...
Link Between Risk of Alzheimer’s Disease and Melanoma, Nonmelanoma Skin Cancers
Although literature demonstrates a decreased risk of Alzheimer's disease in individuals with various cancers—including squamous cell cancers (SCC) and basal cell cancers (BCC)—there is a paucity of literature to substantiate an association between malignant melanoma and...
Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy
The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...
Enormous Cost of Failure to Screen Heavy Smokers for Lung Nodules
In 2011 the American College of Radiology Imaging Network (ACRIN) group published its publicly funded study of three annual screening chest computed tomography (CT) scans among heavy smokers aged 55 to 74.1 The results remain the first and only screening study for any cancer demonstrating a...
mTOR Inhibitor Plus Endocrine Therapy in Postmenopausal Women With Advanced ER-Positive, HER2-Negative Breast Cancer
In the phase II BOLERO-4 trial reported in JAMA Oncology, Royce et al found that the combination of the mTOR inhibitor everolimus (Afinitor) and endocrine therapy was active in first-line treatment of postmenopausal women with advanced estrogen receptor (ER)-positive, human epidermal growth factor...
Phase II Study Shows Durvalumab Active in Patients With Recurrent or Metastatic Head and Neck Cancer
IN A POPULATION of heavily pretreated patients with recurrent or metastatic head and neck cancer and low or negative programmed cell death ligand 1 (PD-L1) expression, durvalumab (Imfinzi) monotherapy demonstrated an overall response rate of 9.2%, consistent with that of single-agent programmed...
EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation
The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small impact on breast cancer risk, according to new research presented at the 11th European Breast...
When Is Active Surveillance Appropriate in the Treatment of DCIS?
In 2017, more than 63,000 women in the United States were diagnosed with in situ breast cancer. The overwhelming majority of those women, about 83%, were diagnosed with ductal carcinoma in situ (DCIS), a condition characterized by the presence of abnormal cells confined to the breast milk ducts;...
Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer
“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...
Raising Awareness of the Link Between Alcohol and Cancer
Prevention in Oncology is guest edited by Jennifer Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer...
Impact of Lifestyle Choices on Outcomes in Survivors of Gastrointestinal Cancers
Physical inactivity among adult survivors of gastrointestinal cancers was tied to poor health-related quality of life, according to researchers at the American Psychosocial Oncology Society (APOS) Annual Meeting.1 Also, physical inactivity (Chi-square = 5.605, P = .018) and alcohol use (Chi-square ...
Expert Point of View: Malcolm K. Brenner, MD, PhD
Discussant for the abstract, Malcolm K. Brenner, MD, PhD, of Baylor College of Medicine Texas Children’s Hospital, underscored the need to make chimeric antigen receptor (CAR) T-cell therapy both safer and more effective. He also noted that overcoming antigen loss with multiple CARs is the next...
Rutgers Cancer Institute Welcomes New Oncology Leadership
RUTGERS CANCER INSTITUTE of New Jersey at the University Hospital in Newark has named several new oncology leaders, further enhancing the facility’s expertise and ability to deliver National Cancer Institute (NCI)-designated comprehensive cancer center services to the greater Essex County region....
Team Wellness: Reflections From Front-Line Clinical Teams
In May 2017, I started to reflect on my own personal views of wellness and the importance of the team. Since that time, I have been fortunate to speak with members of front-line clinical teams from four different practices: Eric Tetzlaff, MSH, PA-C, and Michael Hall, MD, MS, of Fox Chase Cancer...
EXPERT POINT OF VIEW: Brian M. Wolpin, MD, MPH
Invited discussant Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute in Boston, said the results of the LAPACT trial will be useful as an aid to patient counseling as well as in designing and interpreting future studies. However, he added, they are not “practice-changing,” as nanoparticle...
EXPERT POINT OF VIEW: Stephen Leong, MD
STEPHEN LEONG, MD, of the University of Colorado Comprehensive Cancer Center, Aurora, discussed the RAINFALL findings at the symposium, commenting, “The study did meet its primary endpoint of progression-free survival; however, it was disappointing not to see a benefit in overall survival or...
The Toxicity of Time
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Up-to-Date Labels for Older Drugs Essential for Appropriate Use
Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may be missing. Modernizing the labeling process can correct inaccurate information, add data for indications ...
Detecting and Localizing Eight Cancer Types With One Multianalyte Blood Test
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and also helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
Medical Oncologist Takes the Paths Less Traveled to Unwind and Reboot
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment in the Living a Full Life series of articles, Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer ...
Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer
Combinations of targeted therapies (triple, quadruple, or even more) are part of the future of cancer treatment, which means that traditional clinical trials will have to be streamlined and updated to enable greater flexibility and to extract adequate safety and efficacy data. Problems inherent in...
FDA Helps Streamline Approval Process for Supplemental Drug Indications
As researchers learn more about the natural history of cancers, as more drugs are effective for more types of the disease, and as the number and complexity of combination therapies increase, the more important it is that new drugs and permutations of old ones be available to patients. The U.S. Food ...
Broadening the Evidence Base for Older Patients: FDA-ASCO Workshop Explores Emerging Strategies
In the not-so-distant past, clinical trials were considered an option only for the young and fit. Enrolling older people “used to be thought unethical,” said Janet Woodcock, MD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER), as she opened...
Balancing Opioid Use to Relieve Cancer-Related Pain and Protecting Patients From Addiction and Death
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2015, more than 183,000 people have died in the United States from overdoses related to prescription opioids, including methadone, oxycodone, and hydrocodone.1 To stem the epidemic in prescription opioid–related use and ...
Dose-Dense Chemotherapy in Early Breast Cancer: A ‘Win-Win’ Treatment Approach
INCREASING THE DOSE density of chemotherapy lowers the risk of recurrence and breast cancer death by about 15% in women with early breast cancer, according to a large, meticulously conducted meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).1 The trials included in...
Daratumumab Improves Progression-Free Survival in Front-Line Myeloma Setting
FOR NEWLY DIAGNOSED multiple myeloma patients not eligible for transplant, the addition of the anti-CD38 monoclonal antibody daratumumab (Darzalex) to subcutaneous bortezomib (Velcade), melphalan, and prednisone (VMP) reduced the risk of disease progression or death by 50%, the phase III ALCYONE...
Concurrent Palliative Care: Recommendations From the ASCO Clinical Practice Guideline
Updated in 2016, the ASCO clinical practice guideline on the integration of palliative care into standard oncology care provides evidence-based recommendations to oncology clinicians, patients, family and friend caregivers, and palliative care specialists about providing high-quality care for...
SABCS 2017: Increasing the Dose Intensity of Chemotherapy May Lower the Risk of Breast Cancer Recurrence and Death
Increasing the dose intensity of chemotherapy—by either shortening the intervals between the cycles or by sequential administration instead of concurrent administration of the drugs—reduced the risk of early-stage breast cancer recurrence and death compared with standard chemotherapy...
Link Between Cancer and Diabetes, High Body Mass Index
According to the International Agency for Research on Cancer and the World Cancer Research Fund, there is a causal association between a high body mass index (BMI) and 14 cancers, including colorectal, gallbladder, pancreatic, kidney, liver, endometrial, postmenopausal breast, ovarian, gastric...
Where Are We Now in Triple-Negative Breast Cancer?
The treatment of triple-negative breast cancer is rapidly evolving, as clinical trials continue to test chemotherapy agents and combinations and immunotherapy studies promise potentially “game-changing” interventions early in the course of disease, Joyce O’Shaughnessy, MD, reported at the 19th...
New Options for the Management of Hodgkin Lymphoma
With the vast majority of patients cured with primary therapy, classical Hodgkin lymphoma is largely a success story. For the 10% to 20% of patients who either relapse or are refractory to front-line therapy, the disease can still be fatal. At the National Comprehensive Cancer Network® (NCCN®) 12th ...
Model Emphasizes Long-Term Risks of Ovarian Ablation Plus Aromatase Inhibitor
“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. Here Dr. Vogl...
Immunotherapy Plus Radiation Appears Active in Patients With Solid Tumors and Lung or Liver Metastases
THE NOVEL COMBINATION of immunotherapy with ipilimumab (Yervoy) plus radiation achieved a clinical benefit in up to 57% of patients with solid tumors and metastases to the lungs or liver, according to evidence from a phase II trial presented at the 2017 Annual Meeting of the American Society for...
Melatonin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, present information on...
Amended Health Insurance Rule Threatens Key Component of Standard Cancer Treatment
On October 12, ASCO President Bruce E. Johnson, MD, FASCO, issued the following statement: The Trump administration's move to expand the rights of employers to opt out of the requirement for contraceptive coverage would have unexpected and deleterious consequences for patients of childbearing age...
Recognizing the Importance of a Work-Life Balance in Oncology
The ASCO Post introduces this new department, Living a Full Life, in which we will share insightful narratives of oncology professionals highlighting personal aspects of these clinicians’ lives separate from the world of oncology. We also intend to open a dialogue about the challenges that today’s...
Obtaining a Second Graduate Degree During Fellowship: Things to Consider
KAH POH (MELISSA) LOH, MBBCh BAO Institution: Fellow, University of Rochester Medical CenterMember since: 2013ASCO activities: Trainee Council Hematology and oncology fellowship training requires at least 3 years to complete. For fellows who wish to single board in either hematology or oncology, a ...
